menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'CNS' ×
Amir Kalali
The sixth annual CNS Summit , which took place in October, 2015, serves as a platform for innovation in drug development. The event brought together forward thinking drug development professionals and experts in technology and other industries outside drug development. Driven by the principles of collaboration, innovation and technology, the CNS Summit is the place where industry leaders can jointly shape the future of drug development, and that is exactly what this year’s participants set out to do. One significant aspect of the CNS Summit is the diversity of participants. The event draws representatives from pharma, biotech, service companies, site leaders, investors, and patient advocacy groups. Each participant brings their own perspective on clinical research challenges,...
Read More
Olga Uspenskaya-Cadoz
Alzheimer’s Disease (AD) continues to have a devastating toll around the world. Worldwide, approximately 44 million  people have dementia, AD being its most frequent cause. Yet only one-in-four people with the disease have been correctly diagnosed. This is large part due to the fact that until relatively recently, the diagnosis of probable AD could be established only at dementia stage , whereas the definite diagnosis could be certified only by post-mortem brain examination. This lack of diagnosis meant patients with AD couldn’t begin to be treated until after they show noticeable signs of dementia, and even then a “probable diagnosis” of AD could only be concluded after all other potential causes of dementia were eliminated. This created a significant barrier to research, as drugs...
Read More
LynnHughes
Every person has experienced pain in one form or another, and every experience of pain is unique for an infinite number of reasons. The variability, complexity, and risk of abuse can make executing clinical trials for new opioid analgesics a complicated process to plan and manage. Pain is a ubiquitous consequence of a wide range of injuries, surgeries, and medical conditions as diverse as cancer, low-back pain, and restless leg syndrome. Both acute and chronic pain can be extremely debilitating clinical conditions, and there is an ever-present need for analgesic medication. Those patients whose pain is so severe that it requires chronic opioid administration frequently have complex medical conditions, and often react unpredictably to pain medications. Consequently, pain assessments in...
Read More